Stock listing
OTC:ARYX Aryx Therapeutics Inc Stock
Follow Aryx Therapeutics Inc into a list and get an email when it puts out news.
- Ticker
- OTC:ARYX
- Asset type
- Stock
- Exchange
- OTC
- Currency
- USD
Events
| Quarter | Results |
|---|
| Quarter to Sep 30, 2024 | Nov 18, 2024 |
|---|
| Quarter to Jun 30, 2024 | Aug 12, 2024 |
|---|
| Quarter to Mar 31, 2024 | May 16, 2024 |
|---|
| Quarter to Dec 31, 2023 | Mar 25, 2024 |
|---|
| Quarter to Sep 30, 2023 | Nov 13, 2023 |
|---|
| Quarter to Jun 30, 2023 | Aug 14, 2023 |
|---|
| Quarter to Mar 31, 2023 | May 11, 2023 |
|---|
| Quarter to Dec 31, 2022 | Mar 27, 2023 |
|---|
| Quarter to Sep 30, 2022 | Nov 14, 2022 |
|---|
| Quarter to Jun 30, 2022 | Aug 15, 2022 |
|---|
All 16 quarters
| Quarter | Results |
|---|
| Quarter to Mar 31, 2022 | May 12, 2022 |
|---|
| Quarter to Dec 31, 2021 | Mar 28, 2022 |
|---|
| Quarter to Sep 30, 2021 | Nov 15, 2021 |
|---|
| Quarter to Jun 30, 2021 | Aug 16, 2021 |
|---|
| Quarter to Mar 31, 2021 | May 13, 2021 |
|---|
| Quarter to Dec 31, 2020 | Mar 29, 2021 |
|---|
Open Events
Financials
Annual, in USD
Income statement
| Line | FY2009 | FY2008 | FY2007 | FY2006 | FY2005 | FY2004 | FY2003 |
|---|
| Revenue | 0 | 19.7M | 4.16M | 4.74M | | | |
|---|
| Cost of revenue | 0 | 232.0K | 262.0K | 2.12M | 27.4M | | |
|---|
| Gross profit | 0 | 19.5M | 3.90M | 2.62M | | | |
|---|
| Research and development | 21.0M | 40.1M | 25.0M | 24.0M | 22.5M | | 10.7M |
|---|
| Selling, general and administrative | 10.2M | 10.1M | 7.70M | 6.94M | | | |
|---|
| Operating income | -31.2M | -30.4M | -28.8M | -28.3M | -28.2M | -20.8M | -14.1M |
|---|
| Depreciation and amortization | 1.08M | 1.46M | 1.24M | 920.0K | 982.0K | | |
|---|
| EBITDA | -30.2M | -29.0M | -27.6M | -27.4M | -27.2M | | |
|---|
| Interest expense | 2.01M | 1.93M | 1.35M | 1.32M | 671.0K | | 58.0K |
|---|
| Income before tax | -33.2M | -31.2M | -27.6M | -27.3M | | | |
|---|
| Income tax | 849.0K | 801.0K | -1.24M | -960.0K | -205.0K | 20.8M | 14.0M |
|---|
| Net income | -33.2M | -31.2M | -27.6M | -27.3M | -28.0M | -20.8M | -14.0M |
|---|
| Earnings per share, basic | -1.21 | -1.65 | -2.93 | -26.84 | -30.73 | -24.27 | -16.67 |
|---|
Balance sheet
| Line | FY2009 | FY2008 | FY2007 | FY2006 | FY2005 | FY2004 | FY2003 |
|---|
| Cash and equivalents | 7.41M | 36.0M | 55.5M | 18.7M | 12.5M | | |
|---|
| Short-term investments | 353.0K | 8.59M | 7.64M | 31.6M | 13.9M | | |
|---|
| Receivables | | | | 45.0K | | | |
|---|
| Inventory | 0 | 0 | 0 | 0 | | | |
|---|
| Current assets | 8.81M | 45.9M | 64.9M | 51.4M | 27.7M | | |
|---|
| Property, plant and equipment | 2.26M | 3.20M | 3.65M | 4.17M | 4.14M | | |
|---|
| Goodwill | 0 | 0 | 0 | 0 | | | |
|---|
| Total assets | 12.4M | 51.1M | 69.6M | 56.8M | 33.3M | | 8.85M |
|---|
| Accounts payable | 685.0K | 2.45M | 1.37M | 691.0K | 656.0K | | |
|---|
| Current liabilities | 8.68M | 11.0M | 13.5M | 11.5M | 7.75M | | |
|---|
| Long-term debt | 5.28M | 10.2M | 3.44M | 6.68M | 8.92M | | |
|---|
| Total debt | 11.8M | 14.7M | 6.98M | 9.88M | 11.2M | | |
|---|
| Total liabilities | 15.3M | 23.7M | 34.3M | 150.5M | 100.4M | | |
|---|
| Shareholders' equity | -2.92M | 27.4M | 35.3M | -93.7M | -67.1M | | -18.9M |
|---|
| Shares outstanding | 27.4M | 19.0M | 9.41M | 1.02M | 910.0K | 858.0K | 838.0K |
|---|
Cash flow
| Line | FY2009 | FY2008 | FY2007 | FY2006 | FY2005 |
|---|
| Cash from operations | -35.0M | -45.2M | -27.7M | -4.21M | -22.4M |
|---|
| Capital spending | -141.0K | -644.0K | -499.0K | -962.0K | -3.85M |
|---|
| Free cash flow | -35.1M | -45.9M | -28.2M | -5.17M | -26.3M |
|---|
| Cash from investing | 8.41M | -2.41M | 23.4M | -18.5M | 9.53M |
|---|
| Cash from financing | -2.04M | 28.2M | 41.2M | 28.9M | 11.2M |
|---|
| Dividends paid | 0 | 0 | 0 | 0 | |
|---|
| Share buybacks | -92.0K | 0 | 0 | 0 | |
|---|
| Change in cash | -28.6M | -19.5M | 36.8M | 6.21M | -1.73M |
|---|
Open Financials
Cap table
Built by 6ix from Aryx Therapeutics Inc’s releases
- Common shares
- 33,461,975
- Fully diluted
- 33,461,975
Fully diluted
| Line | Shares |
|---|
| Common shares | 33,461,975 |
|---|
Share count over time
| Count | Shares |
|---|
| Nov 22, 2026 | 33,461,975 |
|---|
Open Cap table
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|
Lars G. EkmanOther companies: Prothena Corporation plc (Chair Emeritus · Since at least Dec 20, 2012); Ultragenyx Pharmaceutical Inc. (Director · Mar 17, 2016 – Jun 24, 2022 · Past); Spark Therapeutics Inc (Director · Jan 29, 2015 – Dec 17, 2019 · Past); Ocera Therapeutics Inc (Director · Jul 15, 2013 – Jun 11, 2014 · Past); Amarin Corporation plc (Director · Dec 30, 2010 – Jun 27, 2022 · Past); InterMune Inc (Director · May 10, 2010 – Sep 29, 2014 · Past) | Director · Apr 30, 2010 – Apr 30, 2010 · Past |
|---|
Open People
Log in to ask 6ix AI your own questions about Aryx Therapeutics Inc.